Streetbeat News

TALS

Talaris Therapeutics Inc

Employees

125

Industry

Research and Development in Biotechnology

talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.

Open

2.78

Mkt cap

116M

Volume

303K

High

2.79

P/E Ratio

-1.56

52-wk high

3.29

Low

2.69

Div yield

N/A

52-wk low

0.89

Healthcare stocks experienced significant movement during Thursday's intraday session, with gainers including AGLE, TALS, SENS, SHC, SONN, and INKT, while losers were LUCY, ALVR, MNK, AHI, EVLO, and PIII.

Portfolio Pulse from Benzinga Insights

June 22, 2023 | 5:38 pm

Avid Bioservices shares fell 14.1% after issuing FY24 revenue guidance below estimates. Other stocks experienced significant gains and losses during Thursday's mid-day session, with Aeglea BioTherapeutics climbing 422% after acquiring Spyre Therapeutics and securing a $210 million private investment.

Portfolio Pulse from Lisa Levin

June 22, 2023 | 5:09 pm

The Nasdaq Composite gained over 70 points on Thursday, with consumer discretionary shares rising 1.2%. Aeglea BioTherapeutics acquired Spyre Therapeutics and entered into a definitive agreement for a private placement of Series A non-voting convertible preferred stock, resulting in approximately $210 million in gross proceeds.

Portfolio Pulse from Lisa Levin

June 22, 2023 | 4:11 pm

Talaris Therapeutics and Tourmaline Bio have agreed to merge in an all-stock transaction, with the combined company operating as Tourmaline Bio Inc and trading under the ticker symbol 'TRML'. Talaris stockholders will receive approximately $3.43 per share, and the merger is expected to be completed in Q4 2023.

Portfolio Pulse from Vandana Singh

June 22, 2023 | 3:27 pm

US stocks traded lower following the initial jobless claims report, with the Nasdaq Composite dropping over 150 points. Consumer staples shares rose, while energy shares dipped. Root, Inc. shares shot up after a takeover bid, while AlloVir, Inc. shares dropped after pricing a share offering. Spirit AeroSystems Holdings, Inc. fell after suspending factory operations due to a worker's strike.

Portfolio Pulse from Lisa Levin

June 22, 2023 | 1:41 pm

Talaris Therapeutics and Tourmaline Bio have announced a merger agreement, causing Talaris shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 1:17 pm

12 health care stocks experienced significant price movements during Thursday's pre-market session, with 6 gainers and 6 losers. Aeglea BioTherapeutics, Talaris Therapeutics, T2 Biosystems, Cidara Therapeutics, Navidea Biopharmaceutical, and Predictive Oncology saw gains, while Innovative Eyewear, AlloVir, Advanced Health, Avid Bioservices, LumiraDx, and Genfit experienced losses.

Portfolio Pulse from Benzinga Insights

June 22, 2023 | 1:13 pm

Talaris Therapeutics and Tourmaline Bio have agreed to merge in an all-stock transaction, with the combined company focusing on advancing Tourmaline's lead program, TOUR006. The new company will be named Tourmaline Bio, Inc. and trade under the ticker symbol 'TRML' on Nasdaq. Talaris plans to pay a cash dividend of up to $64.8 million to its stockholders before the merger.

Portfolio Pulse from Benzinga Newsdesk

June 22, 2023 | 11:34 am

Talaris Therapeutics announced that CEO Scott Requadt will be leaving the company as part of a planned workforce reduction. Mary Kay Fenton has been appointed as interim CEO and President effective today.

Portfolio Pulse from Benzinga Newsdesk

May 26, 2023 | 11:02 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.